However, IL-17 has been implicated in the efficacy of BCG immunotherapy in a murine bladder cancer model [25]; although patients with high grade NMIBC should be offered intravesical BCG, not all patients actually receive this treatment. The gene discussed is IL17A; the disease is urinary bladder carcinoma.